Lyra touts positive topline PhII data for chronic rhinosinusitis drug

Katherine Lewin

News Reporter

Lyra Therapeutics debuted positive topline data this morning for one of its lead programs, LYR-220, which aims to treat chronic rhinosinusitis in patients who still …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lyra touts positive topline PhII data for chronic rhinosinusitis drug

Katherine Lewin

News Reporter

Sign up to read this article for free.

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Drug packaging manufacturers brace for impact as EU chemical ban looms

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Lyra touts pos­i­tive topline PhII da­ta for chron­ic rhi­nos­i­nusi­tis drug

Katherine Lewin

News Reporter

Sign up to read this article for free.

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

Drug pack­ag­ing man­u­fac­tur­ers brace for im­pact as EU chem­i­cal ban looms

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Lyra touts positive topline PhII data for chronic rhinosinusitis drug

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Drug packaging manufacturers brace for impact as EU chemical ban looms

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence